Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis

Claudia Bruno; Helga Zoega; Malcolm B. Gillies; Alys Havard; David Coghill; Sallie Anne Pearson; Jonathan Brett

doi:10.1177/00048674231170556

Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis

Claudia Bruno^*, Helga Zoega, Malcolm B. Gillies, Alys Havard, David Coghill, Sallie Anne Pearson, Jonathan Brett

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1073-1076
Number of pages	4
Journal	Australian and New Zealand Journal of Psychiatry
Volume	57
Issue number	7
DOIs	https://doi.org/10.1177/00048674231170556
Publication status	Published - 25 Apr 2023

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This research was supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900) and an NHMRC-European Union (EU) Collaborative Research Grant (ID: APP2007048). C.B. was supported by the Australian Government Research Training Programme Scholarship. The current work was conducted in collaboration with the TIMESPAN research project, which is funded by the European Union’s Horizon 2020 Research and Innovation Programme (ID: 965381). H.Z. was supported by an UNSW Scientia Programme Award. J.B. was supported by an NHMRC Investigator Grant (ID: 1196560). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: S.A.P. is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee; the views expressed in this paper do not represent those of the Committee. D.C. has received honoraria/research funding from Shire/Takeda, Novartis, Bial, Servier and Janssen. He has received royalties from Oxford University Press and Cambridge University Press. The remaining authors report no actual, potential or perceived conflict of interest regarding the submission of this manuscript.

Other keywords

Adult
Humans
Lisdexamfetamine Dimesylate/therapeutic use
Attention Deficit Disorder with Hyperactivity/drug therapy
Central Nervous System Stimulants/therapeutic use
Dextroamphetamine/therapeutic use
Treatment Outcome
Dose-Response Relationship, Drug
Double-Blind Method

Access to Document

10.1177/00048674231170556

Cite this

@article{36097971edad4f3bb23f0d9170aefe1f,

title = "Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis",

keywords = "Adult, Humans, Lisdexamfetamine Dimesylate/therapeutic use, Attention Deficit Disorder with Hyperactivity/drug therapy, Central Nervous System Stimulants/therapeutic use, Dextroamphetamine/therapeutic use, Treatment Outcome, Dose-Response Relationship, Drug, Double-Blind Method",

author = "Claudia Bruno and Helga Zoega and Gillies, {Malcolm B.} and Alys Havard and David Coghill and Pearson, {Sallie Anne} and Jonathan Brett",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This research was supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900) and an NHMRC-European Union (EU) Collaborative Research Grant (ID: APP2007048). C.B. was supported by the Australian Government Research Training Programme Scholarship. The current work was conducted in collaboration with the TIMESPAN research project, which is funded by the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme (ID: 965381). H.Z. was supported by an UNSW Scientia Programme Award. J.B. was supported by an NHMRC Investigator Grant (ID: 1196560). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: S.A.P. is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee; the views expressed in this paper do not represent those of the Committee. D.C. has received honoraria/research funding from Shire/Takeda, Novartis, Bial, Servier and Janssen. He has received royalties from Oxford University Press and Cambridge University Press. The remaining authors report no actual, potential or perceived conflict of interest regarding the submission of this manuscript. ",

year = "2023",

month = apr,

day = "25",

doi = "10.1177/00048674231170556",

language = "English",

volume = "57",

pages = "1073--1076",

journal = "Australian and New Zealand Journal of Psychiatry",

issn = "0004-8674",

publisher = "SAGE Publications Ltd",

number = "7",

}

Bruno, C, Zoega, H, Gillies, MB, Havard, A, Coghill, D, Pearson, SA & Brett, J 2023, 'Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis', Australian and New Zealand Journal of Psychiatry, vol. 57, no. 7, pp. 1073-1076. https://doi.org/10.1177/00048674231170556

Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis. / Bruno, Claudia; Zoega, Helga; Gillies, Malcolm B. et al.
In: Australian and New Zealand Journal of Psychiatry, Vol. 57, No. 7, 25.04.2023, p. 1073-1076.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder

T2 - An interrupted time-series analysis

AU - Bruno, Claudia

AU - Zoega, Helga

AU - Gillies, Malcolm B.

AU - Havard, Alys

AU - Coghill, David

AU - Pearson, Sallie Anne

AU - Brett, Jonathan

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This research was supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900) and an NHMRC-European Union (EU) Collaborative Research Grant (ID: APP2007048). C.B. was supported by the Australian Government Research Training Programme Scholarship. The current work was conducted in collaboration with the TIMESPAN research project, which is funded by the European Union’s Horizon 2020 Research and Innovation Programme (ID: 965381). H.Z. was supported by an UNSW Scientia Programme Award. J.B. was supported by an NHMRC Investigator Grant (ID: 1196560). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: S.A.P. is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee; the views expressed in this paper do not represent those of the Committee. D.C. has received honoraria/research funding from Shire/Takeda, Novartis, Bial, Servier and Janssen. He has received royalties from Oxford University Press and Cambridge University Press. The remaining authors report no actual, potential or perceived conflict of interest regarding the submission of this manuscript.

PY - 2023/4/25

Y1 - 2023/4/25

KW - Adult

KW - Humans

KW - Lisdexamfetamine Dimesylate/therapeutic use

KW - Attention Deficit Disorder with Hyperactivity/drug therapy

KW - Central Nervous System Stimulants/therapeutic use

KW - Dextroamphetamine/therapeutic use

KW - Treatment Outcome

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

UR - http://www.scopus.com/inward/record.url?scp=85153707969&partnerID=8YFLogxK

U2 - 10.1177/00048674231170556

DO - 10.1177/00048674231170556

M3 - Article

C2 - 37122132

AN - SCOPUS:85153707969

SN - 0004-8674

VL - 57

SP - 1073

EP - 1076

JO - Australian and New Zealand Journal of Psychiatry

JF - Australian and New Zealand Journal of Psychiatry

IS - 7

ER -